恶性肿瘤患者接种新型冠状病毒疫苗的建议及依据

Recommendation and basis for inoculation of SARS-CoV-2 vaccines in patients with malignant tumor

新型冠状病毒(SARS-CoV-2)全球大流行已经影响到全世界超过2.18亿人,目前新型冠状病毒肺炎(COVID-19)尚缺乏标准的治疗方案,疫苗的研发与应用将有助于控制COVID-19大流行的状况。当前,世界各国均呼吁加快疫苗接种速度以达到最佳效果的群体免疫。但是,作为COVID-19感染的高危群体,肿瘤患者接种SARS-CoV-2疫苗的安全性及有效性尚缺乏可靠证据。鉴于此,本文将结合SARS-CoV-2的生物学特征、机体的免疫应答反应、疫苗的作用机制及对肿瘤患者的潜在影响几个方面,针对恶性肿瘤患者这一特殊人群能否接种SARS-CoV-2疫苗的相关建议进行总结,以期为恶性肿瘤患者接种疫苗的潜在可能性及风险提供科学的参考依据。

The global severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)pandemic has affected more than 218 million people around the world.Currently,there is no standard therapy for coronavirus disease 2019(COVID-19).The development and application of the vaccines will help control the current COVID-19 pandemic.At present,all countries call for accelerating the vaccination to achieve satisfactory herd immunological results.However,as a high-risk group of COVID-19 infection,there is still a lack of comprehensive evidence on the effectiveness and safety of SARS-CoV-2 vaccines in cancer patients.In view of this,this article combines the biological features of SARS-CoV-2,body immune response,mechanism of action of vaccination and the potential effects on cancer patients,and summarizes the relevant recommendation and evidence on SARS-CoV-2 vaccination of cancer patients,so as to provide scientific reference for the potential possibility and risk of vaccination for patients with malignant tumors.